
    
      This multi-center, open-label, randomized clinical extension study in patients with T1DM will
      assess safety and efficacy of Mylan's insulin glargine and Lantus®.

      Patients with an established diagnosis of T1DM per American Diabetes Association 2014
      criteria who were randomized to the Lantus® treatment arm of the Mylan Glargine 3001 study,
      and who have completed the 52-week treatment period on Lantus® will be eligible to be
      screened for the MYL-1501D-3003 study.
    
  